PROVECTUS BIOPHARMACEUTICALS, INC.

PVCTCIK 0000315545

Analytics Research this company

Financial snapshot

Revenue

Net income

Operating margin

Free cash flow

Total debt

Cash

Research

Filings

Open the filing explorer →

Recent filings load as you scroll to this section.

Analytical signals

How signals work →

Calculations over this company’s filings, each compared with a stated threshold. They indicate where to read more closely; they are analytical evidence, not conclusions, and none implies wrongdoing.

Interest coverage

P-13 · Calculated

Threshold met

FY 2025-12-31

Whether operating earnings cover interest expense, and for how many consecutive years they did not.

Interest coverage below 1.0x for 4 consecutive years (BIS-style test; company age is not checked)

Trend: flat

P-13 inputs
Input	Value
model score (0–100)	100.0
icr_by_year.2025-12-31	-991.901
icr_by_year.2024-12-31	-333.484
icr_by_year.2023-12-31	-513.496
icr_by_year.2022-12-31	-1005.558
consecutive_years_below_1	4
altman_z_double_prime	-1340.017
definitions.zombie	ICR<1 for 3+ consecutive FYs (BIS 2018)
definitions.z_distress	<1.1 distress, 1.1-2.6 gray, >2.6 safe
inputs.ebit_t	-5294765
inputs.interest_expense_t	5338
stale	false
latest_filing_period	2025-12-31

Trend

10-K· 2026-03-26 Methodology

Insider filing timing

P-08 · Calculated

Elevated

FY 2026-07-01

Whether several insiders filed Form 4 in the 14 days before recent 8-K events.

1 8-K event(s) preceded by clustered Form 4 activity within 14 days

P-08 inputs
Input	Value
model score (0–100)	24.0
clusters.0.event_8k	2026-07-01
clusters.0.form4_count	3
clusters.0.form4_dates	["2026-06-30"]
form4_total_1y	44
events_8k_1y	5
window_days	14
note	Timing pattern only — direction (buy/sell) requires parsing each Form 4 XML; treat as a read-the-filings triage flag, not an accusation.

Basis: Insider and event filingsMethodology

Strategic-review language

P-10 · AI-assisted, quote-verified

Elevated

FY 2026-03-26

Activist 13D/13G filings, and language about strategic alternatives in MD&A and risk factors.

5 strategic-language signal(s) in the 10-K

P-10 inputs
Input	Value
model score (0–100)	40.0
sc13d_filings
ai_signals.0.kind	other
ai_signals.0.summary	Pursuing co-development relationships with commercial pharmaceutical companies for PV-10
ai_signals.0.quote	Our goals are to pursue drug approval pathways and/or co-development relationships with commercial pharmaceutical companies for ITU PV-10 based on these indications and data.
ai_signals.0.quote_verified	true
ai_signals.1.kind	other
ai_signals.1.summary	Exploring co-development collaboration or out-license for systemic drug candidate
ai_signals.1.quote	and/or pursue a co-development collaboration or out-license arrangement for this route of administration and disease area
ai_signals.1.quote_verified	true
ai_signals.2.kind	other
ai_signals.2.summary	Exploring co-development collaboration or out-license for other disease areas
ai_signals.2.quote	and/or pursue a co-development collaboration or out-license arrangement for the respective disease area and route of administration
ai_signals.2.quote_verified	true
ai_signals.3.kind	other
ai_signals.3.summary	May relinquish product rights through licensing or other arrangements for funding
ai_signals.3.quote	in the event that additional funds are obtained through licensing or other arrangements, these arrangements may require us to relinquish rights to some of our products, product candidates, and technologies
ai_signals.3.quote_verified	true
ai_signals.4.kind	other
ai_signals.4.summary	Considering corporate collaborations as capital source
ai_signals.4.quote	Management plans to access capital resources through possible public or private equity offerings, including the 2025 Financing, exchange offers, debt financings, corporate collaborations, or other means.
ai_signals.4.quote_verified	true
quotes_discarded_unverified	0
ai_status	ok
method	Deterministic 13D count + LLM language read (quote-verified)

Basis: Filing text (AI-assisted, quote-verified)Methodology

Carbon-exposed assets

P-11 · AI-assisted, quote-verified

Below threshold

FY 2026-03-26

No carbon-exposed asset language detected

How asset-heavy the balance sheet is, and whether the filing names carbon-exposed asset classes.

P-11 inputs
Input	Value
model score (0–100)	0.0
exposures
ppe_share_of_assets	null
quotes_discarded_unverified	0

Basis: Filing text (AI-assisted, quote-verified)Methodology

Language change

P-09 · Calculated

Below threshold

FY 2026-03-26

Filing language stable vs prior 10-K

How the density of uncertainty, negative and litigious wording changed between the latest and prior annual report.

P-09 inputs
Input	Value
model score (0–100)	0.5
current.filed	2026-03-26
current.tokens	30837
current.uncertainty_per_1k	14.14
current.negative_per_1k	5.87
current.litigious_per_1k	2.24
prior.filed	2025-03-28
prior.tokens	29933
prior.uncertainty_per_1k	14.57
prior.negative_per_1k	5.85
prior.litigious_per_1k	2.44
ratios.uncertainty	0.971
ratios.negative	1.004
method	Loughran-McDonald dictionary densities (lite subset unless full CSV present)

Basis: Filing textMethodology

No stored result for Earnings quality, Subsidiary jurisdictions, ESG disclosure support, Effective tax rate, Pension funding, Restatement indicators. Some signals are computed on request, and others need inputs this company’s filings do not tag; a missing result is not a finding either way.

Methodology and sources

Financial figures come from SEC XBRL company facts (annual reports). Choose any evidence marker to see the filing behind a value.
Filing text comes from SEC EDGAR. Browse this company on EDGAR ↗
Signals are calculated by Stratum from those filings. Some use AI to read filing text, and every AI claim must quote the document verbatim or it is discarded. Full methodology

More tools: chat with the 10-K · generate an investigation memo